Title : SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.

Pub. Date : 2021 Sep

PMID : 34002944






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Hydroxychloroquine SMAD family member 4 Homo sapiens
2 We studied whether HCQ treatment in SMAD4 deficient PDA may prevent therapeutic resistance induced by autophagy upregulation. Hydroxychloroquine SMAD family member 4 Homo sapiens
3 The effect of SMAD4 loss on response to HCQ and chemotherapy was studied for association with clinical outcome. Hydroxychloroquine SMAD family member 4 Homo sapiens
4 76% of HCQ-treated patients with SMAD4 loss obtained a histopathologic response greater than or equal to 2A, compared with only 37% with SMAD4 intact (p = 0.006). Hydroxychloroquine SMAD family member 4 Homo sapiens
5 The addition of HCQ to neoadjuvant chemotherapy in patients with PDA may improve treatment response in those with SMAD4 loss. Hydroxychloroquine SMAD family member 4 Homo sapiens